Climbazole

Evidence Level: L2

Predicted Indications: 10

Climbazole
Climbazole: From Topical Antifungal (Anti-Dandruff) Use to Dermatitis (Seborrheic Dermatitis)

## Pharmacist Assessment Report

Using judgment on data selection: among the 10 TxGNN-predicted indications, only rank #3 (“dermatitis,” specifically evidenced as seborrheic dermatitis) has actual clinical/literature support (L2, decision stage S2, “Proceed with Guardrails”). The nominal top-scored candidate (rank #1, “acne keloid”) and 7 others are explicitly flagged in the evidence pack’s own rationale as zero-evidence “model noise” with Hold recommendations. I built the report around the only substantiated candidate rather than the raw highest-score entry, and noted this explicitly for transparency.

Climbazole: From Topical Antifungal (Anti-Dandruff) Use to Dermatitis (Seborrheic Dermatitis)

One-Sentence Summary

Climbazole is an imidazole antifungal agent long used as an active ingredient in anti-dandruff shampoos and topical antifungal creams, though it holds no formal drug marketing authorization in India (0 registrations, “Not Marketed” status). Among 10 TxGNN-predicted indications, only Dermatitis (specifically Seborrheic Dermatitis) is backed by real-world evidence — the model’s higher-scoring candidates (e.g., acne keloid, amyopathic dermatomyositis) returned zero clinical trials and zero literature hits and are annotated in the evidence pack itself as likely embedding artifacts. For Dermatitis, there are currently 0 registered clinical trials but 14 relevant publications, including 3 RCTs directly testing climbazole-containing shampoos/creams against seborrheic dermatitis and dandruff.

Quick Overview

Item	Content
Original Indication	Not formally registered in India/Taiwan; internationally marketed as a topical antifungal active in anti-dandruff shampoos and antimycotic creams
Predicted New Indication	Dermatitis (evidence specifically supports the seborrheic dermatitis subtype)
TxGNN Prediction Score	95.05%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Note on candidate selection: TxGNN’s single highest-scoring prediction (“acne keloid,” 95.32%) and several others (amyopathic dermatomyositis, neonatal dermatomyositis, newborn respiratory distress syndrome, etc.) returned zero clinical trials and zero literature across all queried sources, and are explicitly flagged in the model rationale as mechanistically implausible or likely model noise (all scored L5/Hold). This report instead focuses on the one candidate with real supporting evidence.

Why is This Prediction Reasonable?

Formal DrugBank mechanism-of-action data for climbazole was not available in this evidence pack (flagged as a Blocking/High-severity data gap — see Conclusion). Based on the supporting literature and repurposing rationale collected, climbazole is an imidazole-class antifungal that inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol biosynthesis in the fungal cell membrane. This is the same mechanism shared by other topical azole antifungals.

Its established, long-standing use is in anti-dandruff shampoos and scalp/skin antifungal products, where it suppresses Malassezia species (M. furfur, M. globosa, M. restricta) — the yeast implicated as the principal pathogenic driver of dandruff and seborrheic dermatitis. Since seborrheic dermatitis pathology is directly dependent on Malassezia overgrowth, the mechanistic link between climbazole’s known antifungal activity and this indication is direct and well-established, rather than a novel hypothesis.

Two important caveats apply. First, “Dermatitis” as scored by TxGNN is a broad, unspecific term; the actual literature retrieved supports only the seborrheic dermatitis subtype — it should not be extrapolated to other dermatitis types (e.g., contact dermatitis, atopic dermatitis), which have different underlying pathophysiology and were separately scored by TxGNN (rank #9, “dermatitis, atopic”) with zero supporting evidence. Second, since climbazole-containing anti-dandruff/anti-seborrheic products are already commercially available worldwide (predominantly as cosmetic/OTC shampoo actives rather than as a formally registered pharmaceutical), this finding is best understood as a formalization of an existing, already-marketed use rather than a genuinely novel repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27904273	2016	RCT	Annals of Dermatology	Split-face RCT: climbazole/piroctone olamine cream was effective and well-tolerated for facial seborrheic dermatitis
11534318	2001	RCT	Praxis	Climbazole 0.65% shampoo improved clinical signs of moderate-to-severe scalp seborrheic dermatitis after a 4-week treatment period
21272039	2011	RCT	International Journal of Cosmetic Science	Piroctone olamine 0.5%/climbazole 0.45% shampoo showed efficacy comparable to a 1% zinc pyrithione shampoo in moderate-severe dandruff
31190937	2019	Cohort/Clinical Study	Clinical, Cosmetic and Investigational Dermatology	Assessor-blinded 6-week study: hyaluronic acid cream containing climbazole improved signs, symptoms, and skin microbiota in facial seborrheic dermatitis
38331330	2024	Review/Formulation	International Journal of Pharmaceutics	Characterizes climbazole skin permeation and rational formulation development for dandruff/seborrheic scalp conditions
38544350	2024	In vitro/Preclinical	Journal of Cosmetic Dermatology	Novel shampoo formulations containing climbazole tested against Malassezia species amid emerging azole resistance concerns
26397749	2015	PK/Analytical	Journal of Chromatography B	Validated UHPLC-MS/MS method quantifying climbazole and zinc pyrithione deposition on human scalp from anti-dandruff shampoos
28550716	2017	PK/Ex-vivo	Journal of Pharmaceutical and Biomedical Analysis	Measured climbazole delivery into the scalp follicular infundibulum, relevant to anti-dandruff efficacy
28599021	2017	PK/Imaging	Journal of Biomedical Optics	Stimulated Raman scattering imaging mapped cutaneous distribution of climbazole in dandruff treatment
12858225	2003	Methodology	Journal of Cosmetic Science	Developed the “hair strand test” for evaluating antifungal (antimycotic) efficacy of anti-dandruff preparations

India Market Information

No market authorization records found. Climbazole currently has no registered pharmaceutical license in India (market_status: Not marketed / Not Marketed; total_licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three RCTs and multiple supporting studies directly demonstrate that climbazole-containing topical formulations reduce signs and symptoms of seborrheic dermatitis via well-understood anti-Malassezia activity, giving this candidate L2 evidence — the strongest of all 10 predictions in this pack. However, the guardrail is necessary because evidence supports only the seborrheic dermatitis subtype (not “dermatitis” broadly), the drug has zero market authorization in India, and formal safety/label data is entirely absent.

To proceed, the following is needed:

India-specific regulatory/label safety data (key warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action documentation from DrugBank or another authoritative source — currently a High-severity data gap (DG002)
Drug-drug interaction data (DDI query previously failed due to a missing local data file and returned no results)
Clarification that any future indication claim is scoped specifically to seborrheic dermatitis, not generalized “dermatitis”
A regulatory pathway assessment, since climbazole is not currently a registered pharmaceutical product in India (cosmetic/OTC shampoo use ≠ approved drug indication)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.